我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
相关临床试验
9
8 进行中
药物批准
0
批准总数
监管机构
监管机构数
成立时间
N/A
进行中（未招募）
8
88.9%
已完成
1
11.1%
暂无批准数据
- French biotech Pharnext's lead drug PXT3003 for Charcot-Marie-Tooth disease type 1A failed to demonstrate superiority over placebo in Phase 3 PREMIER trial due to unexpected placebo response. - Despite the setback, Pharnext remains optimistic, citing 10 years of accumulated data and an ongoing Phase 3 trial with Chinese partner Tasly that could support regulatory submission. - PXT3003, a combination of baclofen, naltrexone, and sorbitol, maintained its favorable safety profile and showed no disease deterioration in treated patients during the study period.
